| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 11, 2024 | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ) | Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
Mon, Nov 11, 2024 08:00 CET Report this content
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Ex... |
| Nov 5, 2024 | Sobi's New Leadership: A Strategic Shift in the Biopharmaceutical Landscape | In the ever-evolving world of biopharmaceuticals, leadership changes can signal new directions and strategies. Recently, Swedish Orphan Biovitrum AB (Sobi) announced the nomination of David Meek as the new Chair of the Board of Directors. T... |
| Nov 5, 2024 | Navigating Change in Biopharma: Leadership Shifts at Senhwa and Sobi | The biopharmaceutical landscape is a dynamic arena, where leadership changes can signal new directions and strategies. Recently, two companies, Senhwa Biosciences and Swedish Orphan Biovitrum AB (Sobi), have made significant appointments th... |
| Nov 4, 2024 | David Meek is proposed as new Chair of the Board of Directors of Sobi | David Meek is proposed as new Chair of the Board of Directors of Sobi
Mon, Nov 04, 2024 21:00 CET Report this content
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of... |
| Oct 19, 2018 | Term Sheet — Friday, October 19 | THE BIG BIRD RACE
Good morning. Polina is off today and will return next week. In place of this morning’s essay is a brand-new report by Lucinda Shen on the rise of electric scooter chargers—the people behind the multibillion-dollar busines... |
| Oct 18, 2018 | Novartis spends $2.1B to snap up targeted radiotherapy drug for prostate cancer | The radioligand therapy, or RLT, uses a ligand, or small molecule that is designed to bind to a protein expressed on the surfaces of most prostate cancer cells – but not normal cells – called prostate-specific membrane antigen, according to... |
| Oct 3, 2018 | Endocyte raises another $189M | |
| Apr 7, 2014 | Endocyte raises another $100M in stock offering | |
| Mar 17, 2014 | OnTarget Labs lands $15M for tumor fluorescing tech | OnTarget Laboratories said it landed a $15 million investment from a pair of backers for its tumor-lighting technology developed at Purdue University by the founder of Endocyte (NSDQ:ECYT).
The OnTarget technology uses small molecules and f... |
| Apr 16, 2012 | Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic | Endocyte will receive an equal share of the profit in the United States if vintafolide receives regulatory approval, along with a double-digit percentage royalty on sales of the product in the rest of the world. It will keep the right to co... |
| Mar 15, 2012 | Basketball or biomedicine? Indiana’s March Madness schools win at both | Not to take the focus away from the Hoosier state regaining some of its basketball gusto, but in recognition of these schools’ other outstanding accomplishments, here are some of the most interesting medical companies to spin out of these t... |
| Feb 4, 2011 | Cancer drugmaker Endocyte raises $75 million in IPO | |
| Jan 28, 2011 | Endocyte plans to raise about $78 million in IPO | |
| Aug 26, 2010 | Endocyte’s $86M IPO plan a boon for Indiana, investors | |
| Aug 18, 2010 | Cancer drug developer Endocyte files for $86M IPO | Endocyte’s small-molecule drug conjugates “actively target receptors that are over-expressed on diseased cells,” the company said in its registration statement. This targeting enables patients to be treated with highly active drugs or high ... |
| Oct 16, 2009 | Endocyte Closes $26M Equity Financing | Endocyte Inc., a cancer drug discovery and development company, completed a $26m extension of its Series C financing round.
This round included existing institutional investors Sanderling Ventures, Burrill & Co., American Bailey Venture... |
| Oct 16, 2009 | Cancer drug business Endocyte raises $26 million | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Oct 16, 2009 | Endocyte receives $26M infusion from investors | |
| Jan 25, 2008 | Endocyte lands $15M credit line | |
| Novartis spends $2.1B to snap up targeted radiotherapy drug for prostate cancer | Swiss drugmaker Novartis made a big investment in radiopharmaceuticals with the Thursday announcement that it will acquire a US firm with an oncology drug in late-stage development.
The company said it would acquire Endocyte, headquartered ... |
| Cancer drug developer Endocyte files for $86M IPO | West Lafayette, Indiana, biopharmaceutical company Endocyte Inc. hopes to raise more than $86 million from an initial public offering of stock.
The company that develops small-molecule drug “conjugates” to treat cancer and inflammatory dise... |
| Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic | Merck (NYSE:MRK) has forged a deal with a biopharmaceutical company for its phase 3 platinum-resistant ovarian cancer treatment and nonsmall cell lung cancer in mid-stage development in a deal valued at up to $1 billion.
Under the terms of ... |
| Cancer drug business Endocyte raises $26 million | WEST LAFAYETTE, Indiana — The cancer drug developer Endocyte has raised $26 million it will use to help complete a study for its ovarian cancer treatment.
The company is in the midst of a Phase 2 trial on an ovarian drug that works with wom... |
| Basketball or biomedicine? Indiana’s March Madness schools win at both | What do Purdue University, Indiana University and the University of Notre Dame have in common — besides that they’re Indiana teams playing the 2012 NCAA tournament?
They’re all great schools for medical innovation and have produced notewort... |
